Top Markets
#1 ADO Protocol ADO Protocol +329.02%
#2 GoPlus Security GoPlus Security +53.91%
#3 Nockchain Nockchain +48.00%
#4 Starpower Starpower +34.71%
#5 Tutorial Tutorial +34.11%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +32.30%
#7 The Black Bull The Black Bull +30.82%
#8 GAIB AID GAIB AID +24.67%
#9 Verus Coin Verus Coin +20.20%
#10 Fake World Assets Fake World Assets +18.08%
Coin of the day
ADO Protocol ADO Protocol
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
PhoenixBio Co., Ltd. PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.

6190
Clasificación en acciones #32816
PhoenixBio Co., Ltd. delivers specialized contract research services to support... PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Precio por acción
$2.22
Capitalización bursátil
$9.03M
Cambio (1 día)
-3.13%
Cambio (1 año)
-21.92%
País
JP
Comercio PhoenixBio Co., Ltd. (6190)

Categoría

Healthcare
Ganancias de PhoenixBio Co., Ltd. (6190)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di PhoenixBio Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de PhoenixBio Co., Ltd. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE